Empery Asset Management LP Purchases Shares of 8,951,105 X4 Pharmaceuticals, Inc. $XFOR

Empery Asset Management LP purchased a new stake in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 8,951,105 shares of the company’s stock, valued at approximately $35,804,000. X4 Pharmaceuticals makes up about 31.7% of Empery Asset Management LP’s investment portfolio, making the stock its biggest position. Empery Asset Management LP owned 10.24% of X4 Pharmaceuticals as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the company. Nantahala Capital Management LLC purchased a new position in X4 Pharmaceuticals during the third quarter valued at approximately $7,621,000. Rosalind Advisors Inc. purchased a new position in X4 Pharmaceuticals during the third quarter valued at approximately $5,283,000. Deep Track Capital LP purchased a new position in X4 Pharmaceuticals during the third quarter valued at approximately $3,839,000. Geode Capital Management LLC lifted its holdings in X4 Pharmaceuticals by 1,080.6% during the fourth quarter. Geode Capital Management LLC now owns 940,447 shares of the company’s stock valued at $3,764,000 after purchasing an additional 860,789 shares in the last quarter. Finally, Kingdon Capital Management L.L.C. lifted its holdings in X4 Pharmaceuticals by 300.0% during the third quarter. Kingdon Capital Management L.L.C. now owns 933,332 shares of the company’s stock valued at $3,192,000 after purchasing an additional 700,000 shares in the last quarter. Hedge funds and other institutional investors own 72.03% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Leerink Partners assumed coverage on shares of X4 Pharmaceuticals in a report on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 price target on the stock. Wall Street Zen raised shares of X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Weiss Ratings downgraded shares of X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 4th. Finally, Guggenheim initiated coverage on shares of X4 Pharmaceuticals in a report on Monday, March 9th. They issued a “buy” rating and a $12.00 target price on the stock. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.38.

X4 Pharmaceuticals Price Performance

XFOR stock opened at $3.73 on Thursday. X4 Pharmaceuticals, Inc. has a one year low of $1.35 and a one year high of $4.83. The company’s fifty day moving average price is $4.10 and its 200-day moving average price is $3.88. The company has a debt-to-equity ratio of 0.45, a quick ratio of 9.98 and a current ratio of 10.18. The company has a market capitalization of $351.81 million, a PE ratio of -0.82 and a beta of 0.34.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. X4 Pharmaceuticals had a negative net margin of 1,106.30% and a negative return on equity of 94.90%. The company had revenue of $2.71 million for the quarter, compared to analysts’ expectations of $3.20 million. On average, equities analysts anticipate that X4 Pharmaceuticals, Inc. will post -0.77 EPS for the current fiscal year.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.